Amphenol Corporation (NYSE:APH) reported its results for the fourth quarter. Net income for the diversified electronics company fell to $113.9 million (69 cents per share) vs. $131.1 million (74 cents per share) a year earlier. This is a decline of 13.2% from the year earlier quarter. Revenue  fell 0.1% to $948.7 million from the year earlier quarter. APH reported adjusted net income of 73 cents per share. By that measure, the company beat the mean estimate of 70 cents per share. Analysts were expecting revenue of $932.3 million.

Amphenol President and Chief Executive Officer R. Adam Norwitt stated “We are pleased to report strong performance in a very challenging environment in the quarter with fourth quarter sales of $949 million, operating income margin (excluding one-time items) of 18.5% and earnings per share (excluding one-time items) of $.73. Global markets have been impacted by a higher level of uncertainty related in part to the fiscal and budgetary issues in many developed economies.”

Competitors to Watch: Molex Incorporated (NASDAQ:MOLX), RF Industries, Ltd. (NASDAQ:RFIL), TE Connectivity Ltd. (NYSE:TEL), Thomas & Betts Corporation (NYSE:TNB), Methode Electronics Inc. (NYSE:MEI), Optical Cable Corporation (NASDAQ:OCCF), Spectrum Control, Inc. (NASDAQ:SPEC), CommScope, Inc. (NYSE:CTV), AVX Corporation (NYSE:AVX), and Belden Inc. (NYSE:BDC).

Forest Laboratories Inc. (NYSE:FRX) reported its results for the third quarter. Net income for Forest Laboratories Inc. fell to $278.4 million ($1.04 per share) vs. $320.7 million ($1.11 per share) a year earlier. This is a decline of 13.2% from the year earlier quarter. Revenue  rose 9.2% to $1.21 billion from the year earlier quarter. FRX beat the mean analyst estimate of $1.01 per share. It beat the average revenue estimate of $1.18 billion.

Howard Solomon, Chairman and Chief Executive Officer of Forest, said: “We are pleased with the financial performance of the Company reported this quarter and with the continued positive progress of our new product launches. In the quarter, excluding the small increase for Lexapro, we had a sales increase of $91 million which included a $20.6 million increase for Namenda whose patent expires in 2015. The remaining $70.4 million of growth is principally attributable to Bystolic, Savella, Teflaro, Viibryd and Daliresp, all five new products with patents expiring in the next decade.”

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), AstraZeneca plc (NYSE:AZN), Lannett Company, Inc. (AMEX:LCI), Watson Pharmaceuticals, Inc. (NYSE:WPI), Mylan Inc. (NASDAQ:MYL), Pfizer Inc. (NYSE:PFE), Abbott Laboratories (NYSE:ABT), Impax Laboratories, Inc. (NASDAQ:IPXL), Par Pharmaceutical Companies, Inc. (NYSE:PRX), and Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ).

Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!